3 completed, 2 terminated, 1 active not recruiting. 6 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 3, Terminated 2, Active not recruiting 1 |
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
Follow Methamphetamine Use Disorder: new trials by email Literature Review of Methamphetamine Use Disorder trials Research Report on Methamphetamine Use Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Deep Brain Stimulation (DBS) for Methamphetamine Use Disorder Experimental 1 - DBS of bilateral NAc - 6 months of active stimulation -- > 6 months of sham stimulation, Experimental 2 - DBS of bilateral NAc - 6 months of sham stimulation -- > 6 months of active stimulation - Methamphetamine Use Disorder | Phase 1 / Phase 2 | Active not recruiting | University of Colorado, Denver | 2 | 2024-01-15 | 2025-04-30 |
| Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder Psilocybin - Methamphetamine Use Disorder, Substance-Related Disorders | Phase 1 | Terminated | University of Wisconsin, Madison | 5 | 2023-03-03 | 2026-05-12 |
| Mirtazapine and Methamphetamine Drug-drug Interaction Study Mirtazapine, Methamphetamine - Methamphetamine Use Disorder, Drug Interaction | Phase 1 | Completed | San Francisco Department of Public Health | 15 | 2021-05-03 | 2024-09-27 |
| Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine] Methamphetamine, Methylphenidate, Placebo oral capsule - Methamphetamine Use Disorder | Phase 1 | Completed | Craig Rush | 8 | 2019-09-01 | 2023-01-09 |
| Study of Pomaglumetad and Methamphetamine Pomaglumetad methionil, Placebo, Methamphetamine - Methamphetamine Use Disorder | Phase 1 | Terminated | University of California, Los Angeles | 19 | 2017-08-01 | 2020-09-01 |
| Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder naltrexone plus bupropion - Methamphetamine Use Disorder | Phase 1 / Phase 2 | Completed | Walter Ling | 49 | 2013-11-01 | 2020-03-23 |
Cardiovascular Abnormalities (1) · Chemically-Induced Disorders (1) · Substance-Related Disorders (1)
Cardiovascular Diseases (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Mental Disorders (1)
Methamphetamine (3) · Bupropion (1) · Duloxetine Hydrochloride (1) · Lactose (1) · Methylphenidate (1) · Mirtazapine (1) · Naltrexone (1) · Psilocybin (1) · pomaglumetad methionil (1)
Craig Rush (1) · San Francisco Department of Public Health (1) · University of California, Los Angeles (1) · University of Colorado, Denver (1) · University of Wisconsin, Madison (1) · Walter Ling (1)
United States (6)
Christopher Nicholas, PhD (1) · Keith Heinzerling, MD (1) · Larissa Mooney, M.D. (1) · Phillip Coffin, MD, MIA (1) · Walter Ling, M.D. (1)
R01DA043238 (1), R01DA047391 (1), U10DA013045 (1), UG3DA054746 (1)